SC Slams 10x Cancer Drug Markup: Carnage for Patients
The Supreme Court of India recently raised alarm over the steep cancer drug markup observed across private hospitals. During recent hearings, the bench termed this tenfold price disparity absolute carnage against vulnerable families. Consequently, the top court urged the Centre to re-evaluate pharmaceutical pricing frameworks immediately.
Severe Cancer Drug Markup Under Judicial Scrutiny
The division bench comprising Justice Vikram Nath and Justice Sandeep Mehta highlighted stark commercial disparities in life-saving oncology medications. Specifically, the judges pointed out an essential oncology drug carrying a Maximum Retail Price (MRP) of Rs 27,000 despite a Price to Retailer (PTR) of only Rs 2,700. Thus, patients encounter an unconscionable ten-fold price escalation at hospital counters. Moreover, the judges questioned where this substantial excess revenue flows and who truly benefits from the transaction. Solicitor General Tushar Mehta acknowledged the gravity of the situation during proceedings. Furthermore, he observed that pharmaceutical manufacturers do not capture these margins, pointing instead toward private healthcare institutions.
Hospital Chemist Mandates and Public Schemes
In addition to exorbitant retail prices, the bench addressed anti-competitive dispensary mandates enforced by private healthcare establishments. Many corporate hospitals compel admitted patients to purchase all medications solely from in-house pharmacies. Consequently, facilities often refuse to assure clinical treatment if attendants procure identical therapies from external vendors. Justice Mehta emphasized that this system directly exploits public funds when beneficiaries access government welfare schemes. Because taxpayers reimburse these inflated bills, unmonitored profit margins severely drain state resources. Therefore, the bench insisted that the Centre must implement uniform pricing benchmarks across all clinical settings.
Expanding DPCO Price Controls and Generic Prescribing
The bench advocated for a uniform 16 percent trade margin on Maximum Retail Price for all medicinal formulations. Under the Drugs (Prices Control) Order (DPCO) 2013, statutory ceiling prices currently govern only scheduled drugs. However, non-scheduled formulations represent more than 80 percent of the domestic market by both volume and value. As a result, pharmaceutical manufacturers enjoy substantial latitude to establish elevated initial prices subject only to annual ten percent escalation caps. The ongoing public interest litigations also demand strict disciplinary mechanisms against physicians who fail to prescribe affordable generic alternatives. Hence, comprehensive regulatory reforms remain imperative to protect vulnerable citizens from catastrophic health expenditures.
Frequently Asked Questions
Q1: Why did the Supreme Court characterize cancer medicine pricing as carnage?
The bench highlighted that hospitals sell oncology drugs with a trade price of Rs 2,700 at an MRP of Rs 27,000. This drastic tenfold markup imposes catastrophic financial stress on families and public healthcare funds.
Q2: What regulatory solution did the Supreme Court propose during the hearing?
The judges proposed establishing a uniform 16 percent retail profit margin on all medicines under the DPCO framework, rather than restricting price ceilings to scheduled formulations alone.
Q3: How does the hospital chemist mandate affect patients?
Many hospitals require admitted individuals to buy medications strictly from internal counters at marked-up prices, preventing families from acquiring verified, discounted formulations from external pharmacies.
References
- 'This is carnage', says SC on markup of 10 times on cancer drugs by hospitals - ETHealthworld
- Supreme Court questions steep mark-ups on cancer drugs, calls pricing disparity 'carnage' - The Hindu
- Why Not Cap Medicines' MRPs At 16% Above Retailer Prices? Supreme Court Asks - LiveLaw
